146 related articles for article (PubMed ID: 9732993)
1. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy.
Schlageter MH; Larghero J; Cassinat B; Toubert ME; Borschneck C; Rain JD
Clin Chem; 1998 Sep; 44(9):1995-8. PubMed ID: 9732993
[No Abstract] [Full Text] [Related]
2. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.
Pectasides D; Economides N; Bourazanis J; Pozadzizou P; Gogou L; Koutsiouba P; Athanassiou A
Am J Clin Oncol; 1994 Aug; 17(4):307-12. PubMed ID: 8048392
[TBL] [Abstract][Full Text] [Related]
3. [Serum tumor markers SCC, TATI and TPS: value in follow-up of females with cervix cancer].
Joura E; Gitsch G; Kainz C; Fröhlich B; Biegelmayr C; Kölbl H
Gynakol Geburtshilfliche Rundsch; 1992; 32 Suppl 1():115. PubMed ID: 1286308
[No Abstract] [Full Text] [Related]
4. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
6. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer.
Pectasides D; Bourazanis J; Economides N; Pozadzidou P; Gogou L; Koutsiouba P; Athanassiou A
Int J Biol Markers; 1993; 8(2):81-7. PubMed ID: 8366300
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma.
Hoffmann J; Munz A; Krimmel M; Alfter G
J Oral Maxillofac Surg; 1998 Dec; 56(12):1390-3. PubMed ID: 9846535
[TBL] [Abstract][Full Text] [Related]
10. Tumour marker detection in oesophageal carcinoma.
Mealy K; Feely J; Reid I; McSweeney J; Walsh T; Hennessy TP
Eur J Surg Oncol; 1996 Oct; 22(5):505-7. PubMed ID: 8903494
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers with clinically controlled cut-offs for suspected cancer.
Bosch X; Molina R; Marrades R; Augé JM; Pellicé M; López-Soto A
Eur J Clin Invest; 2021 Jul; 51(7):e13523. PubMed ID: 33594702
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of squamous cell carcinoma antigen and carcinoembryonic antigen as tumor markers of vulvar cancer.
Yamawaki T; Takeshima N; Shimizu Y; Teshima H; Hasumi K
J Obstet Gynaecol Res; 1996 Aug; 22(4):341-6. PubMed ID: 8870416
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of squamous cell carcinoma antigen in cancer of the human uterine cervix. Comparison with CEA and CA-125.
Verlooy H; Devos P; Janssens J; Mortelmans L; Gerits M; Bonte J; De Roo M
Gynecol Obstet Invest; 1991; 32(1):55-8. PubMed ID: 1765320
[TBL] [Abstract][Full Text] [Related]
15. [Tumoral markers in liver cirrhosis and hepatocellular carcinoma].
Gómez Rubio M; de Cuenca Morón B; Domínguez M
Gastroenterol Hepatol; 2005 May; 28(5):308. PubMed ID: 15871818
[No Abstract] [Full Text] [Related]
16. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in the treatment of cancer: opportunities and pitfalls.
Melichar B
Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
[No Abstract] [Full Text] [Related]
18. Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response.
Leminen A; Alftan H; Stenman UH; Lehtovirta P
Acta Obstet Gynecol Scand; 1992 May; 71(4):293-7. PubMed ID: 1322623
[TBL] [Abstract][Full Text] [Related]
19. The lack of utility of a tumor marker panel in head and neck carcinoma. Squamous cell carcinoma antigen, carcinoembryonic antigen, lipid-associated sialic acid, and CA-125.
Straka MB; Wagner RL; Johnson JT; Kachman KK; Eibling DE
Arch Otolaryngol Head Neck Surg; 1992 Aug; 118(8):802-5. PubMed ID: 1642830
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tumour markers in molar pregnancy.
Hegab HM; Schindler AE; Rizk M; Ramadan M
Arch Gynecol Obstet; 2003 Aug; 268(3):151-4. PubMed ID: 12942241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
